| Title |
Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome
|
|---|---|
| Published in |
Annals of Intensive Care, July 2014
|
| DOI | 10.1186/s13613-014-0022-z |
| Pubmed ID | |
| Authors |
Kathleen D Liu, Jennifer G Wilson, Hanjing Zhuo, Lizette Caballero, Melanie L McMillan, Xiaohui Fang, Katherine Cosgrove, Carolyn S Calfee, Jae-Woo Lee, Kirsten N Kangelaris, Jeffrey E Gotts, Angela J Rogers, Joseph E Levitt, Jeanine P Wiener-Kronish, Kevin L Delucchi, Andrew D Leavitt, David H McKenna, B Taylor Thompson, Michael A Matthay |
| Abstract |
Despite advances in supportive care, moderate-severe acute respiratory distress syndrome (ARDS) is associated with high mortality rates, and novel therapies to treat this condition are needed. Compelling pre-clinical data from mouse, rat, sheep and ex vivo perfused human lung models support the use of human mesenchymal stem (stromal) cells (MSCs) as a novel intravenous therapy for the early treatment of ARDS. |
Mendeley readers
The data shown below were compiled from readership statistics for 90 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 1% |
| France | 1 | 1% |
| Brazil | 1 | 1% |
| Unknown | 87 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 17 | 19% |
| Student > Bachelor | 12 | 13% |
| Student > Ph. D. Student | 9 | 10% |
| Student > Master | 9 | 10% |
| Other | 6 | 7% |
| Other | 17 | 19% |
| Unknown | 20 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 36% |
| Agricultural and Biological Sciences | 7 | 8% |
| Biochemistry, Genetics and Molecular Biology | 6 | 7% |
| Nursing and Health Professions | 6 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Other | 8 | 9% |
| Unknown | 28 | 31% |